131 related articles for article (PubMed ID: 38382910)
1. Microglia cells treated with synthetic vasoactive intestinal peptide or transduced with LentiVIP protect neuronal cells against degeneration.
Goksu AY; Kocanci FG; Akinci E; Demir-Dora D; Erendor F; Sanlioglu S; Uysal H
Eur J Neurosci; 2024 Apr; 59(8):1993-2015. PubMed ID: 38382910
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma.
Delgado M; Ganea D
FASEB J; 2003 Oct; 17(13):1922-4. PubMed ID: 12923064
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs.
Toscano MG; Delgado M; Kong W; Martin F; Skarica M; Ganea D
Mol Ther; 2010 May; 18(5):1035-45. PubMed ID: 20068554
[TBL] [Abstract][Full Text] [Related]
4.
Kim HL; Min DE; Lee SK; Choi BK; Lee DR
J Med Food; 2023 May; 26(5):328-341. PubMed ID: 37092995
[TBL] [Abstract][Full Text] [Related]
5. Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation.
Erendor F; Sahin EO; Sanlioglu AD; Balci MK; Griffith TS; Sanlioglu S
Gene Ther; 2021 Apr; 28(3-4):130-141. PubMed ID: 32733091
[TBL] [Abstract][Full Text] [Related]
6. In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis.
Delgado M; Toscano MG; Benabdellah K; Cobo M; O'Valle F; Gonzalez-Rey E; Martín F
Arthritis Rheum; 2008 Apr; 58(4):1026-37. PubMed ID: 18383372
[TBL] [Abstract][Full Text] [Related]
7. HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes.
Tasyurek HM; Eksi YE; Sanlioglu AD; Altunbas HA; Balci MK; Griffith TS; Sanlioglu S
Gene Ther; 2018 Jul; 25(4):269-283. PubMed ID: 29523882
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide-induced neurite remodeling in human neuroblastoma SH-SY5Y cells implicates the Cdc42 GTPase and is independent of Ras-ERK pathway.
Alleaume C; Eychène A; Harnois T; Bourmeyster N; Constantin B; Caigneaux E; Muller JM; Philippe M
Exp Cell Res; 2004 Oct; 299(2):511-24. PubMed ID: 15350548
[TBL] [Abstract][Full Text] [Related]
9. Additive cell protective and oxidative stress reducing effects of combined treatment with cromolyn sodium and masitinib on MPTP-induced toxicity in SH-SY5Y neuroblastoma cells.
Goksu Erol AY; Kocanci FG; Demir-Dora D; Uysal H
Chem Biol Interact; 2022 Feb; 354():109808. PubMed ID: 35007524
[TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.
Offen D; Sherki Y; Melamed E; Fridkin M; Brenneman DE; Gozes I
Brain Res; 2000 Jan; 854(1-2):257-62. PubMed ID: 10784133
[TBL] [Abstract][Full Text] [Related]
11. The metabolite GLP-1 (9-36) is neuroprotective and anti-inflammatory in cellular models of neurodegeneration.
Li Y; Glotfelty EJ; Karlsson T; Fortuno LV; Harvey BK; Greig NH
J Neurochem; 2021 Dec; 159(5):867-886. PubMed ID: 34569615
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia.
Delgado M; Leceta J; Ganea D
J Leukoc Biol; 2003 Jan; 73(1):155-64. PubMed ID: 12525573
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels.
Delgado M; Varela N; Gonzalez-Rey E
Glia; 2008 Aug; 56(10):1091-103. PubMed ID: 18442091
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation.
Delgado M; Ganea D
FASEB J; 2003 May; 17(8):944-6. PubMed ID: 12626429
[TBL] [Abstract][Full Text] [Related]
15. VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress.
Steingart RA; Solomon B; Brenneman DE; Fridkin M; Gozes I
J Mol Neurosci; 2000 Dec; 15(3):137-45. PubMed ID: 11303778
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
Delgado M; Jonakait GM; Ganea D
Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
[TBL] [Abstract][Full Text] [Related]
17. Pimecrolimus protects neuron-like SH-SY5Y cells against anti-inflammatory and anti-oxidant effects of both microglial secretome and hydrogen peroxide.
Kocanci FG; Erol AYG; Yildiz F; Eciroglu H
Scand J Immunol; 2024 Jan; 99(1):e13328. PubMed ID: 38441277
[TBL] [Abstract][Full Text] [Related]
18. HCH6-1, an antagonist of formyl peptide receptor-1, exerts anti-neuroinflammatory and neuroprotective effects in cellular and animal models of Parkinson's disease.
Wang HL; Cheng YC; Yeh TH; Liu HF; Weng YH; Chen RS; Chen YC; Lu JC; Hwang TL; Wei KC; Liu YC; Wang YT; Hsu CC; Chiu TJ; Chiu CC
Biochem Pharmacol; 2023 Jun; 212():115524. PubMed ID: 37001680
[TBL] [Abstract][Full Text] [Related]
19. The effects of vasoactive intestinal peptide in neurodegenerative disorders.
Deng G; Jin L
Neurol Res; 2017 Jan; 39(1):65-72. PubMed ID: 27786097
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide-induced neuritogenesis in neuroblastoma SH-SY5Y cells involves SNAP-25.
Héraud C; Chevrier L; Meunier AC; Muller JM; Chadéneau C
Neuropeptides; 2008; 42(5-6):611-21. PubMed ID: 18617262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
